DIALYSIS GUIDELINES

CARI Guidelines mission is to improve the quality of care and outcomes for patients with kidney disease in Australia & New Zealand by facilitating the development and implementation of trustworthy clinical practice guidelines based on the best available evidence and effectiveness.

All Guidelines published more than 5 years ago have been moved to Archived Guidelines.

Biochemical and Haematological TargetsStatus
MINERAL AND BONE DISORDER (MBD)
HaemoglobinNov 2011
IronJul 2013
GUIDELINE SUMMARIES
KHA-CARI guideline: Biochemical and haematological targets: Haemoglobin concentrations in patients using erythropoietin-stimulating agents. McMahon LP, Macginley R. Nephrology 2012; 17(1): 17-9.
KHA-CARI Guideline: Use of iron in chronic kidney disease patients. MacGinley R, Walker R, Irving M. Nephrology 2013; 18(12): 747-9.

Readers of these guidelines are advised to also refer to the guidelines contained in the “Vitamin D, Calcimimetics and Phosphate Binders” (Chronic Kidney Disease) section.

All Guidelines published more than 5 years ago have been moved to Archived Guidelines.

Biochemical and Haematological TargetsStatus
MINERAL AND BONE DISORDER (MBD)
HaemoglobinNov 2011
IronJul 2013
GUIDELINE SUMMARIES
KHA-CARI guideline: Biochemical and haematological targets: Haemoglobin concentrations in patients using erythropoietin-stimulating agents. McMahon LP, Macginley R. Nephrology 2012; 17(1): 17-9.
KHA-CARI Guideline: Use of iron in chronic kidney disease patients. MacGinley R, Walker R, Irving M. Nephrology 2013; 18(12): 747-9.

Readers of these guidelines are advised to also refer to the guidelines contained in the “Vitamin D, Calcimimetics and Phosphate Binders” (Chronic Kidney Disease) section.